![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » A&G PHARMACEUTICAL AND CELLTRION ANNOUNCE BIOPROCESS DEVELOPMENT & MANUFACTURING AGREEMENT
A&G PHARMACEUTICAL AND CELLTRION ANNOUNCE BIOPROCESS DEVELOPMENT & MANUFACTURING AGREEMENT
June 7, 2006
A&G Pharmaceutical, Inc. and Celltrion, Inc. have entered into an agreement for clinical production of a novel A&G theranostic monoclonal antibody. Celltrion will perform bioprocess development, scale-up, and cGMP manufacturing and provide all clinical materials to support toxicology studies as well as Phase I and Phase II U.S. clinical studies on A&G's anti-GP88 monoclonal antibody.
PR Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct